S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.23 (+0.48%)
FB   219.76 (-0.70%)
MSFT   166.72 (+0.62%)
GOOGL   1,484.69 (+0.04%)
AMZN   1,884.58 (-0.15%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.13 (-1.46%)
MU   59.20 (+0.05%)
GE   11.77 (+3.52%)
TSLA   572.20 (+0.46%)
AMD   51.71 (+0.54%)
T   38.63 (-1.05%)
ACB   2.07 (+1.47%)
F   9.14 (-0.22%)
NFLX   349.60 (+7.24%)
BAC   34.12 (-0.70%)
DIS   142.20 (-1.26%)
GILD   63.94 (+0.80%)
S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.23 (+0.48%)
FB   219.76 (-0.70%)
MSFT   166.72 (+0.62%)
GOOGL   1,484.69 (+0.04%)
AMZN   1,884.58 (-0.15%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.13 (-1.46%)
MU   59.20 (+0.05%)
GE   11.77 (+3.52%)
TSLA   572.20 (+0.46%)
AMD   51.71 (+0.54%)
T   38.63 (-1.05%)
ACB   2.07 (+1.47%)
F   9.14 (-0.22%)
NFLX   349.60 (+7.24%)
BAC   34.12 (-0.70%)
DIS   142.20 (-1.26%)
GILD   63.94 (+0.80%)
S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.23 (+0.48%)
FB   219.76 (-0.70%)
MSFT   166.72 (+0.62%)
GOOGL   1,484.69 (+0.04%)
AMZN   1,884.58 (-0.15%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.13 (-1.46%)
MU   59.20 (+0.05%)
GE   11.77 (+3.52%)
TSLA   572.20 (+0.46%)
AMD   51.71 (+0.54%)
T   38.63 (-1.05%)
ACB   2.07 (+1.47%)
F   9.14 (-0.22%)
NFLX   349.60 (+7.24%)
BAC   34.12 (-0.70%)
DIS   142.20 (-1.26%)
GILD   63.94 (+0.80%)
S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.23 (+0.48%)
FB   219.76 (-0.70%)
MSFT   166.72 (+0.62%)
GOOGL   1,484.69 (+0.04%)
AMZN   1,884.58 (-0.15%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.13 (-1.46%)
MU   59.20 (+0.05%)
GE   11.77 (+3.52%)
TSLA   572.20 (+0.46%)
AMD   51.71 (+0.54%)
T   38.63 (-1.05%)
ACB   2.07 (+1.47%)
F   9.14 (-0.22%)
NFLX   349.60 (+7.24%)
BAC   34.12 (-0.70%)
DIS   142.20 (-1.26%)
GILD   63.94 (+0.80%)
Log in

NASDAQ:DXCM - DexCom Stock Price, Forecast & News

$235.60
+0.06 (+0.03 %)
(As of 01/23/2020 04:00 PM ET)
Today's Range
$231.69
Now: $235.60
$237.79
50-Day Range
$202.18
MA: $222.46
$239.27
52-Week Range
$107.44
Now: $235.60
$242.14
Volume582,895 shs
Average Volume831,140 shs
Market Capitalization$21.56 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.76
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:DXCM
CUSIP25213110
Phone858-200-0200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.03 billion
Cash Flow$0.64 per share
Book Value$7.47 per share

Profitability

Net Income$-127,100,000.00

Miscellaneous

Employees2,800
Market Cap$21.56 billion
Next Earnings Date2/13/2020 (Confirmed)
OptionableOptionable

Receive DXCM News and Ratings via Email

Sign-up to receive the latest news and ratings for DXCM and its competitors with MarketBeat's FREE daily newsletter.


DexCom (NASDAQ:DXCM) Frequently Asked Questions

What is DexCom's stock symbol?

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) announced its earnings results on Wednesday, November, 6th. The medical device company reported $0.65 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.20 by $0.45. The medical device company had revenue of $396.30 million for the quarter, compared to analysts' expectations of $348.99 million. DexCom had a positive return on equity of 16.16% and a negative net margin of 12.68%. DexCom's quarterly revenue was up 48.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.17 earnings per share. View DexCom's Earnings History.

When is DexCom's next earnings date?

DexCom is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for DexCom.

How can I listen to DexCom's earnings call?

DexCom will be holding an earnings conference call on Thursday, February 13th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has DexCom issued on next quarter's earnings?

DexCom issued an update on its fourth quarter 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $457-457 million, compared to the consensus revenue estimate of $431.47 million.

What price target have analysts set for DXCM?

15 brokerages have issued twelve-month price targets for DexCom's shares. Their forecasts range from $125.00 to $255.00. On average, they expect DexCom's share price to reach $207.43 in the next twelve months. This suggests that the stock has a possible downside of 12.0%. View Analyst Price Targets for DexCom.

What is the consensus analysts' recommendation for DexCom?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 4 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DexCom.

What are Wall Street analysts saying about DexCom stock?

Here are some recent quotes from research analysts about DexCom stock:
  • 1. According to Zacks Investment Research, "Strong contributions from the Sensor and Transmitter segments remain key catalysts for DexCom. Further, solid guidance instills optimism in the stock. The glucose monitoring market presents significant commercial opportunity for DexCom. Opportunities in alternative markets such as the non-intensive diabetes management space, hospital, gestational, pre-diabetes and obesity are likely to provide DexCom a competitive edge in the MedTech space. DexCom exited the third quarter on a strong note, wherein both earnings and revenues beat the Zacks Consensus Estimate. Shares of the company have outperformed the industry in a year's time. Meanwhile, cutthroat competition in the market for blood & glucose monitoring devices remains a headwind." (1/8/2020)
  • 2. Northland Securities analysts commented, "We present here a comparative assessment of 2.0 data readouts. Our global view is….we love Dexcom, but believe the story is going to be pressured on all fronts….top-line growth, margins, and market share. If this data is representative of the FDA submission (or part thereof), there is no doubt that Libre 2.0 will get an i" designation." (6/6/2019)

Has DexCom been receiving favorable news coverage?

News coverage about DXCM stock has been trending positive on Thursday, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. DexCom earned a media sentiment score of 2.2 on InfoTrie's scale. They also gave news stories about the medical device company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for DexCom.

Who are some of DexCom's key competitors?

What other stocks do shareholders of DexCom own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), Alibaba Group (BABA), Paypal (PYPL), salesforce.com (CRM), Netflix (NFLX), Home Depot (HD), ServiceNow (NOW), Micron Technology (MU), Veeva Systems (VEEV) and Tandem Diabetes Care (TNDM).

Who are DexCom's key executives?

DexCom's management team includes the folowing people:
  • Mr. Kevin R. Sayer, Exec. Chairman, CEO & Pres (Age 61)
  • Mr. Quentin S. Blackford, Exec. VP & CFO (Age 40)
  • Mr. Steven R. Pacelli, Exec. VP of Strategy & Corp. Devel. (Age 47)
  • Mr. Andrew K. Balo, Exec. VP of Clinical Affairs, Regulatory Strategies & Global Access (Age 71)
  • Mr. Richard B. Doubleday, Exec. VP & Chief Commercial Officer (Age 56)

Who are DexCom's major shareholders?

DexCom's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Chicago Capital LLC (0.21%), Peregrine Capital Management LLC (0.10%), Patten & Patten Inc. TN (0.02%), Johanson Financial Advisors Inc. (0.01%), Janney Montgomery Scott LLC (0.01%) and Gateway Investment Advisers LLC (0.01%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Donald Abbey, Eric Topol, Heather S Ace, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Doubleday, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg. View Institutional Ownership Trends for DexCom.

Which institutional investors are selling DexCom stock?

DXCM stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Tocqueville Asset Management L.P., Gateway Investment Advisers LLC, Chicago Capital LLC, Nisa Investment Advisors LLC, CenturyLink Investment Management Co, Janney Montgomery Scott LLC and Weatherly Asset Management L. P.. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Doubleday, Steven R Altman and Steven Robert Pacelli. View Insider Buying and Selling for DexCom.

Which institutional investors are buying DexCom stock?

DXCM stock was purchased by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., DNB Asset Management AS, Assenagon Asset Management S.A., HWG Holdings LP, Campbell & CO Investment Adviser LLC, IFM Investors Pty Ltd, Exchange Traded Concepts LLC and Zeke Capital Advisors LLC. View Insider Buying and Selling for DexCom.

How do I buy shares of DexCom?

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is DexCom's stock price today?

One share of DXCM stock can currently be purchased for approximately $235.60.

How big of a company is DexCom?

DexCom has a market capitalization of $21.56 billion and generates $1.03 billion in revenue each year. The medical device company earns $-127,100,000.00 in net income (profit) each year or $0.30 on an earnings per share basis. DexCom employs 2,800 workers across the globe.View Additional Information About DexCom.

What is DexCom's official website?

The official website for DexCom is http://www.dexcom.com/.

How can I contact DexCom?

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]


MarketBeat Community Rating for DexCom (NASDAQ DXCM)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  807 (Vote Outperform)
Underperform Votes:  507 (Vote Underperform)
Total Votes:  1,314
MarketBeat's community ratings are surveys of what our community members think about DexCom and other stocks. Vote "Outperform" if you believe DXCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DXCM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Featured Article: Quantitative Easing

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel